ZYBERNO
Stock Report
Updated Aug 31, 2026

Axogen, Inc. (AXGN)

Healthcare • NASDAQ

$51.47

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
35.0/100
WEAK BUSINESS
Axogen, Inc. (AXGN) scores 35/100 — weak fundamentals with mixed indicators requiring careful analysis before acting.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
MARGIN OF SAFETY
Is this stock cheap or expensive relative to what the business has historically generated for owners?
-100.0%
Overvalued
Growth gap unavailable — insufficient data for reverse DCF calculation.
🎯 Expected Annual Return
-21.7%
Margin of Safety convergence — your return if the market re-prices to intrinsic value (5-yr annualised)
-1.0%
Yield + growth — what the business alone earns you, even if the market never re-rates
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-17.9%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.26x)
Operating Margin (Operational Efficiency):CRITICAL (-5.1%)
Return on Capital (Capital Efficiency):CRITICAL (-4.6%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Axogen, Inc. (AXGN) stock report — Zyberno Score 35/100 (WEAK BUSINESS), Margin of Safety -100.0%, -22% expected annual return. Full financial analysis on Zyberno.

According to Zyberno's DCF model, Axogen, Inc. (AXGN) trades at $51.47 against an estimated intrinsic value per share of $6.10 — a -100.0% Margin of Safety based on Owner Earnings of $10.46M TTM, projected at 74.8% growth for 10 years with a 2.5% terminal growth rate. Zyberno's model translates this into a 5-year expected return of -21.7% annually.

Over the trailing twelve months, AXGN generated $10.46M in Owner Earnings. Capital was deployed as follows: $6.28M invested in capital expenditures. Reinvestment rate: 30.3%. Owner Earnings have grown at 74.8% annually over the trailing five years using log-linear regression.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:51.47
Market Cap:$2.75B

Valuation Multiples (3)

P/B Ratio:10.71x
P/S Ratio:10.93x
Peg Ratio:-999.00x

Enterprise Metrics (2)

Enterprise Value:$2.70B
Pfcf Ratio:295.90x

Price Action & Momentum (3)

Momentum Percentile:99 / 100
% of 52-Week High:99.0%
B. Profitability Assessment

Return Metrics (5)

ROA:-13.0%
Reinvestment Rate:30.3%
Fundamental Growth Rate (g):-1.4%

Margin Analysis (3)

Operating Margin Ttm:-5.1%
Net Margin Ttm:-13.4%
Ebitda Margin:-2.3%

TTM Performance (3)

Gross Margin Ttm:74.6%
Operating Margin Ttm:-5.1%
Net Margin Ttm:-13.4%

Yield Metrics (3)

Earnings Yield:-$1.32
Owner Earnings Yield:$0.38
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-366.7%
Latest Earnings Filed:2026-07-29

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):18.8%

Cash Flow Growth (Linear) (2)

Free Cash Flow Growth Rate (Linear):-37.2%
Operating Cash Flow Growth Rate (Linear):57.0%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:6.60x
Quick Ratio:5.04x
Cash Ratio:3.11x

Leverage Analysis (3)

Debt To Equity Ttm:0.26x
Debt-to-Equity Ratio:0.26x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-1.88x
Times Interest Earned:-1.88

Capital Structure (4)

Working Capital:170,002,000.00
Cash And Cash Equivalents:94,572,000.00
Long Term Debt:$18.07M
Net Debt:-$48.10M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $251.17M
Linear Growth: 18.8%
📊 Click to view full AXGN Revenue analysis & methodology →
Cost Of Revenue Ttm:$63.91M

Profitability Breakdown (2)

Gross profit TTM: $187.27M
Linear Growth: 14.7%
📊 Click to view full AXGN Gross Profit analysis & methodology →
-$12.85M

Bottom Line Performance (3)

-$33.55M
Income Before Tax:$0.00
Ebitda Ttm:-5,747,000.00

Operating Expenses (5)

Operating Expenses:200,113,000.00
R And D Expense:36,047,000.00
Sga Expense:51,715,000.00
Income Tax Expense:$0.00
Interest Expense:4,170,000.00

Expense Ratios (3)

R And D To Revenue Percentage:51.7%
Sga To Revenue Percentage:74.2%
Ebitda Margin:-2.3%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$304.86M
Current Assets:$200.38M
Ppe Net:0.00
Goodwill:0.00
Intangible Assets:$7.57M

Liability Structure (4)

Total Liabilities:48,606,000.00
Current Liabilities:30,374,000.00
Long Term Debt:$18.07M
Short Term Debt:$28.40M

Equity & Capital (3)

Equity:$256.26M
Retained Earnings:-$328.06M
Common Stock:100,000,000.00

Working Capital Items (3)

Accounts Receivable:34,126,000.00
Inventory:47,313,000.00
Accounts Payable:28,399,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:6,843,000.00
C. Cash Flow Analysis

Operating Activities (2)

Operating cash flow TTM: $15.56M
Linear Growth: 57.0%
Free cash flow TTM: $9.28M
Linear Growth: -37.2%
📊 Click to view full AXGN Free Cash Flow analysis & methodology →

Investment Activities (2)

Investing Cash Flow:-$15.96M
Capital Expenditures Ttm:6,278,000.00

Financing Activities (3)

Financing Cash Flow:$59.51M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:134,044,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:7,101,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.68
-$0.68
Earnings Per Share Ttm:-$0.63

Revenue & Cash Per Share (3)

Sales Per Share Ttm:4.71
Operating Cash Flow Per Share:$0.02
Fcf Per Share Ttm:0.17

Book Value & Capital (2)

Book Value Per Share:$4.80
Cash Per Share:1.77

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.97x
Working Capital Turnover Ttm:1.48x

Receivables Management (2)

Receivables Turnover Ttm:7.36x
Days Sales Outstanding Ttm:49.59

Inventory Management (2)

Inventory Turnover Ttm:1.35x
Days Inventory Outstanding Ttm:270.22

Payables & Cash Cycle (2)

Days Payable Outstanding:162.19
Cash Conversion Cycle:157.61
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:50.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (3)

Owner earnings TTM: $10.46M
Linear Growth: 74.8%
📊 Click to view full AXGN Owner Earnings analysis & methodology →
Owner Earnings Per Share:$0.20
Owner Earnings Yield:$0.38

Growth Assessment (1)

Owner Earnings Growth Rate:$74.80

Damodaran Growth Analysis (2)

Reinvestment Rate:30.3%
Fundamental Growth Rate (g):-1.4%

Intrinsic Value Models (1)

Return Scenarios (2)

Investment Assessment (1)

Buffett Assessment:Overvalued
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):18.8%

Cash Flow Growth Rates (2)

Free Cash Flow Growth Rate (Linear):-37.2%
Operating Cash Flow Growth Rate (Linear):57.0%

Other Growth Rates (3)

Gross Profit Growth Rate (Linear):14.7%
Book Value Growth Rate (Linear):16.2%
Owner Earnings Growth Rate:$74.80
C. Company Profile & Context

Corporate Information (6)

Symbol:AXGN
Company Name:Axogen, Inc.
Sector:Healthcare
Industry:Medical Technology
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:high
Volume Category:N/A

Share Structure (3)

Shares Outstanding:53.34M
Shares Outstanding Basic:53.34M
Shares Outstanding Diluted:53.34M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-31 04:27:10 UTC
Data Timestamp:2026-08-31T04:27:10.615647
Scroll to Top